Home › Coronary Artery Disease › NCT06235112
AI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention
AI Detection of Incidental Coronary Artery Calcium to Enhance Cardiovascular Disease Prevention: A Multicenter Randomized Trial
Who can join
Ages 40 to 75 · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients aged between 40-75 with prior chest CT within last 3 years Exclusion Criteria: * Prior coronary artery disease * Prior cancer * Other life-limiting condition
About the study
AI INFORM is a multicenter randomized trial that will test the hypothesis that providing clinicians information on the presence and amount of coronary artery calcifications (CAC), will result in initiation or intensification of preventive therapies. The study will use a cloud-based artificial intelligence (AI) platform (Nanox.AI) that can analyze non contrast chest CT and estimate the amount of CAC.
What is being tested
- Electronic health record-based notification of Nanox.AI Coronary Artery Calcification Assessment (device)
Sponsor: Brigham and Women's Hospital · Participants: 1,500 · Started: Jul 31, 2024
Contact the study team
Official record on ClinicalTrials.gov — NCT06235112
Locations in the U.S.
| Massachusetts | Brigham and Women's Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.